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OBJECTIVE — To evaluate through early preclinical atherosclerosis assessment whether re-
peated episodes of hypoglycemia represent an aggravating factor for macrovascular disease in
type 1 diabetes.
RESEARCH DESIGN AND METHODS — After sample-size calculation, a case-control
studyof25patientswithtype1diabetesandrepeatedsevere/nonseverehypoglycemia(H-group)
compared with 20 age- and sex-matched type 1 diabetes control subjects (C-group) was de-
signed. Assessment of preclinical atherosclerosis consisted of ﬂow-mediated brachial dilatation
(FMD) and carotid and femoral intima-media thickness (IMT) studies. To consider hypoglyce-
mia awareness, two different questionnaires and symptomatic response to an acute induction to
hypoglycemia were used. Evaluation of the glycemic proﬁle was obtained from continuous
glucose monitoring. Endothelial function/inﬂammation markers were measured in euglycemia/
hypoglycemia. A multivariate linear regression analysis was performed to test whether repeated
hypoglycemia was independently associated with atherosclerosis.
RESULTS — H-group subjects displayed hypoglycemia unawareness and presented a higher
percentageofcontinuousglucosevaluesandareaunderthecurve70mg/dlcomparedwiththe
C-group(14.28.9vs.6.37.1%,P0.02and2.41.8vs.0.61.0mg/dl/day,P0.01).
ThepercentageofmaximalFMDwaslowerintheH-groupthanintheC-group(6.522.92vs.
8.62  3.13%, P  0.05). A signiﬁcantly higher IMT was observed at both carotid and femoral
sitesintheH-group(carotid0.530.09vs.0.470.08mm,P0.05andfemoral0.510.17
vs. 0.39  0.09 mm, P  0.05). Baseline inﬂammation and endothelial function markers were
higher in the H-group (leukocytes 7.0  1.8 vs. 5.6  1.4  10
3/ml, von Willebrand factor
119  29 vs. 93  26%, ﬁbrinogen 2.82  0.64 vs. 2.29  0.44g/l, and soluble intercellular
adhesion molecule-1 408  224 vs. 296  95 ng/ml; P  0.05 for all).
CONCLUSIONS — In addition to the induction of hypoglycemia unawareness and an in-
creasedriskforseverehypoglycemia,repeatedhypoglycemiacouldberelatedtoandconsidered
an aggravating factor for preclinical atherosclerosis in type 1 diabetes. The precise mechanisms
explaining this association remain to be clariﬁed.
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E
venthoughmanyofthecardiovascu-
lar disease (CVD) risk factors recog-
nized in type 2 diabetes are not
present in type 1 diabetic subjects, the
age-adjusted relative risk for CVD in type
1 diabetes is even higher than that in type
2 diabetes (1). Since the availability of
data from Diabetes Control and Compli-
cations Trial (DCCT)/Epidemiology of
Diabetes Interventions and Complica-
tions (EDIC) studies, there is no doubt
that intensive therapy positively affects
the long-term incidence of micro- and
macrovascular disease in subjects with
type 1 diabetes (2,3). However, because
the association between glycemic control
and macrovascular disease is mainly ob-
tainedfromepidemiologicaldata,therole
of glycemic control in macrovascular dis-
ease is still controversial. In contrast, in-
tensive glucose control invariably
increases the risk of hypoglycemia.
Iatrogenic hypoglycemia causes re-
current morbidity in most people with
type 1 diabetes. Frequent and repeated
episodes of hypoglycemia almost unfail-
ingly result in a reduced ability or failure
to recognize hypoglycemia symptoms
and signs. This syndrome of hypoglyce-
mia unawareness frequently occurs in
type 1 diabetes, and patients without
warning symptoms are then at a high risk
for severe hypoglycemia (4). In addition,
hypoglycemiaisamajorbarriertoachiev-
ing normoglycemia over a lifetime of us-
ing intensive insulin therapy and thus
precludesthelong-termbeneﬁtsofeugly-
cemia (4). More recently, Gill et al. (5)
reported QT prolongation and cardiac
and rhythm disturbances in response to
nocturnal hypoglycemia in ambulatory
patients with type 1 diabetes, which may
support the idea of an arrhythmic basis
for “death in bed syndrome.”
Carotid intima-media thickness
(cIMT) and the assessment of endothelial
function have been shown to be markers
of preclinical atherosclerosis and corre-
late with prevalent and incident cardio-
vascular disease (6). In the DCCT/EDIC,
theprogressionofcIMTinthepopulation
of type 1 diabetic subjects was used as a
measure of atherosclerosis (7).
It has also been reported that patients
with type 1 diabetes presented higher
cIMT and lower percentages of ﬂow-
mediated dilatation (FMD) with respect
to healthy control subjects (8). Although
hyperglycemia has been proven to in-
crease the stiffness of intermediate-sized
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analysis of discontinuous glucose proﬁle
datasets from the DCCT failed to ﬁnd an
association between glucose variability
and the development of microvascular
complications (9). Moreover, various
measures for the assessment of glycemic
variability have shown that there is no re-
lationship between oxidative stress and
glucose ﬂuctuations in type 1 diabetes
eventhoughglucosevariabilitywasmuch
higher than that in type 2 diabetes (10).
Acute hypoglycemia induces a rapid
proinﬂammatory, platelet aggregatory,
antiﬁbrinolytic, and prothrombotic re-
sponse (11,12). Recurrent hypoglycemic
episodes may provoke changes in hemo-
static factors and viscosity, which may
reduce perfusion in diabetic microangi-
opathy(11,12).Rodriguesetal.(13)have
recently reported that higher ﬁbrinogen
levels predict progression of coronary ar-
tery calciﬁcation in adults with type 1 di-
abetes. The SEARCH study has also
described elevated inﬂammatory markers
even in youth with type 1 diabetes and
good metabolic control compared with
control subjects, suggesting an explana-
tionforacceleratedatherosclerosisintype
1 diabetes (14). In addition, Feldman-
Billard et al. (15) described hypoglyce-
mia-induced hypertension in a group of
diabetic patients. If hypoglycemia acutely
provokes intense changes in hemody-
namics and several hemorheological pa-
rameters, it could play a different role in
atherosclerosis when chronically
repeated.
Therefore,theaimofourstudywasto
evaluatewhetherrepeatedepisodesofhy-
poglycemia represent an aggravating fac-
tor for macrovascular disease in subjects
withtype1diabetesthroughearlyathero-
sclerosis-vascular assessment.
RESEARCH DESIGN AND
METHODS— A total of 45 patients
withtype1diabeteswererecruitedforthe
study from 2007 to 2009. Subjects were
invited to participate in the protocol if
they fulﬁlled the following criteria: aged
18 years, type 1 diabetes duration 5
years, basal C-peptide 0.1 ng/ml, use of
multiple doses of insulin in a basal-bolus
schedule, and an absence of other major
CVD risk factors, micro- or macrovascu-
lar complications (normal digital retinal
photography results, absence of mi-
croalbuminuria, no neuropathy by clini-
cal examination, normal ankle-brachial
index, and normal stress echocardiogra-
phy results), and no autonomic dysfunc-
tion (Cardionomic system; Medimatica,
Milan, Italy). Patients were not taking
medicationchronically(includingstatins,
antihypertensive drugs, or anti-
inﬂammatory drugs) except insulin.
Of the 45 type 1 diabetic patients, 25
were selected as a hypoglycemic group
(H-group) presenting 4 nonsevere hy-
poglycemia episodes per week (last 8
weeks) and 2 severe hypoglycemia epi-
sodes in the past 2 years. All episodes of
capillary glycemia 70 mg/dl were con-
sidered nonsevere hypoglycemia epi-
sodes based on four to six daily capillary
blood determinations. Severe hypoglyce-
mia events were deﬁned as those associ-
ated with neuroglycopenia severe enough
torequiretreatmentfromathirdparty.Of
the 45 type 1 diabetic patients, 20 were
chosen as age- and sex-matched diabetic
controlsubjects(C-group)presenting2
nonsevere hypoglycemia episodes per
week (last 8 weeks) and with no previous
episodesofseverehypoglycemia.Anthro-
pometric measures, general biochemical
parameters, A1C values (normal range
3.5–5.5%; Menarini Diagnostici, Firenze,
Italy), and lipid proﬁle were measured at
the beginning of the study.
In addition, an age- and sex-matched
healthy control group (22 subjects) was
selected as a comparative group for ultra-
sound analysis. They satisﬁed the criteria
of being nonsmokers, having a normal
fasting glycemia and lipid proﬁle, not
having hypertension, diabetes, or dyslip-
idemia, and not having a family history of
CVD or diabetes.
The protocol included an evaluation
of the frequency/awareness of hypoglyce-
mia, an assessment of glycemic proﬁle/
glucose variability, an evaluation of
endothelialfunction(FMD),andacarotid
and femoral IMT assessment. Inﬂamma-
tion and endothelial function markers
were evaluated.
The study protocol, conducted ac-
cording to the Declaration of Helsinki,
was approved by the Hospital Clínic i
Universitari Ethics Committee. Informed
consentwasobtainedfromallthepatients
and control subjects.
Evaluation of hypoglycemia
awareness
Two different questionnaires (Clarke and
Gold tests [16,17]) were used to evaluate
hypoglycemia awareness. To assess signs
andsymptomsresponsetoastandardized
situation of hypoglycemia, an acute in-
duction to hypoglycemia with intrave-
nous insulin was performed (18).
Subjects with type 1 diabetes answered
the Hypoglycemia symptoms score ques-
tionnaire (Edinburgh scale [19]) after 30
min of euglycemia ﬁrst (80–120 mg/dl)
and after 30 min of hypoglycemia (45–55
mg/dl) afterward. The tests scores for the
twostateswerecompared,andtheresults
are expressed as a percentage of increase
from the baseline.
Glycemic proﬁle and glucose
variability
Immediatelybeforevascularstudies,each
patient with type 1 diabetes underwent
continuous glucose monitoring (CGM)
for72husingtheMedtronicGoldsystem.
Glucose variability was evaluated by cal-
culating mean amplitude of glucose ex-
cursions(MAGE)fromcontinuoussensor
readings. MAGE over 24 h is the mean of
the absolute differences between glucose
peak and nadir values in excess of at least
1 SD of the mean glucose.
Ultrasound imaging
The carotid, femoral, and brachial artery
ultrasound studies were performed with
an Acuson Sequoia system (Acuson Cor-
poration, Mountain View, CA), equipped
with an 8-MHz linear array transducer.
The FMD studies were performed by
M.G., a trained endocrinologist with ex-
periencein150FMDstudies.ThecIMT
and femoral IMT (fIMT) studies were
done by R.G., a radiologist with 15
years of experience. M.G. and R.G. were
masked to the patient groups when they
performed the FMD and IMT studies.
FMD. All patients and healthy control
subjects were evaluated after6ho fabsti-
nence from food and caffeinated drinks.
Women were examined in the follicular
phase of the menstrual cycle. Capillary
glycemia was always between 80 and 120
mg/dl. The brachial artery was imaged
longitudinally5–10cmabovetheantecu-
bitalfossa.Baselineimageswererecorded
continuously for 1 min. Subsequently, a
blood pressure cuff positioned 4 cm be-
low the elbow was inﬂated up to 250
mmHg for 5 min. The artery was contin-
uously imaged for 4 min during the hy-
peremia after release of the cuff pressure
to determine endothelium-dependent va-
sodilatation.Allimageswereanalyzedus-
ing proprietary software (Brachial
Analyzer; Medical Imaging Applications,
Iowa City, IA). Dilatation was calculated
asmaximallumendiameterafterischemia
minuslumendiameteratbaselinedivided
bylumendiameteratbaseline.Resultsare
expressed as a percentage.
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carotid artery bulb, and the internal ca-
rotid artery near and far wall segments
werescannedbilaterally.IMTwasdeﬁned
as the distance between the lumen-intima
and the media-adventitia interfaces. Mea-
surements were performed ofﬂine and
consisted of six manual measurements at
equal distances along 1 cm on the far wall
of the common carotid artery (1 cm be-
fore the bifurcation), bulb, and internal
carotid artery (1 cm after the bifurcation).
The mean of the 36 values for right and
left sides was considered a composite
measurement (cIMTcomp). Atheroma
plaques (focal intrusions into the lumen
withaheight50%ofthenearestIMTor
diffuse IMT thickening 1.2 mm) were
sought by using B-mode and color Dopp-
ler imaging in all the carotid segments.
fIMT. Mean fIMT was measured in the
far arterial wall along the distal 1 cm be-
fore the bifurcation. Six measurements
were done manually on each side. fIMT
was expressed as the mean of the 12
values.
Intraobserver variability was evalu-
ated by comparing results from repeated
examinations of 15 subjects on 2 days a
week apart. The correlation coefﬁcients
for cIMT, fIMT, and percent FMD were
0.91, 0.93, and 0.74, respectively. The
correlationcoefﬁcientbetweentwodiffer-
ent readers was 0.91 for cIMT.
Inﬂammation and endothelial
marker evaluation
After type 1 diabetic patients had rested
30 min in euglycemia, leukocytes, high-
sensitivity C-reactive protein (hs-CRP)
(Behring Nephelometer analyzer; Dade
Behring, Marburg, Germany), von Wille-
brand factor (vWF) (ELISA-based com-
mercial kit, DG-EIA vWF; Diagnostic
Grifols, Parets del Valles, Spain), ﬁbrino-
gen (Thromborel S; Dade-Behring), solu-
ble intercellular adhesion molecule-1
(sICAM-1) (ELISA-based commercial kit;
BKL Diagnostics, Barcelona, Spain), solu-
ble E-selectin (ELISA-based commercial
kit; BKL Diagnostics), and interleukin-1
(1-IL) (ELISA-based commercial kit;
BioSource Europe, Nivelles, Belgium)
were measured to assess inﬂammation
and endothelial function. All of these pa-
rameters were also measured after 30 min
in hypoglycemia.
Statistical analysis
Results are presented as means  SD or
percentages. Normal distribution was
testedforeachvariableusingtheKolmog-
orov-Smirnov test. The comparisons be-
tween groups were performed using a
Student’s t test for unpaired data for nor-
mally distributed variables or using a
Mann-Whitney U test for nonnormally
distributed variables. Proportions were
compared with the use of a Fisher exact
test. A multivariate linear regression anal-
ysis was performed to test whether re-
peated hypoglycemia was independently
associated with cIMTcomp measure-
ments. Covariates included age, sex, co-
morbidities(systolicbloodpressure,BMI,
and LDL cholesterol) and factors related
to diabetes and glucose control (type 1
diabetes duration, A1C, and MAGE). P 
0.05 was considered statistically signiﬁ-
cant. All statistical calculations were per-
formed with SPSS (version 14.0 for
personal computers).
Sample size calculation
We planned a study of a continuous re-
sponsevariablefromindependentcontrol
subjects(C-group)andexperimentalsub-
jects(H-group).Consideringatruediffer-
ence in the experimental and control
means of 0.045 mm in cIMT, we needed
to study at least 20 experimental subjects
and20controlsubjectstobeabletoreject
the null hypothesis that the population
means of the experimental and control
wereequalwithprobability(power)0.80.
The type I error probability associated
with this test of this null hypothesis was
0.05 ().
RESULTS— The baseline characteris-
tics of the H-group and C-group are
shown in Table 1. There were no major
differencesinthewholesetofclinicaland
laboratory parameters between type 1 di-
abetic subjects and healthy control
subjects.
Hypoglycemia awareness and
number of hypoglycemic episodes
As expected, H-group subjects had a sig-
niﬁcantly higher number of nonsevere
hypoglycemia episodes per week and
more severe hypoglycemia episodes than
type 1 diabetic subjects in the C-group
(nonsevere hypoglycemia: 5.22  1.98
vs. 0.25  0.50 episodes/week/subject
during the previous 2 weeks, P  0.01;
severe hypoglycemia for 2 years before:
1.28  0.45 vs. 0 episodes/patient/year).
Hypoglycemia awareness was evalu-
atedusingtwodifferentspeciﬁcquestion-
naires. The Gold questionnaire classiﬁed
25of25subjectsintheH-groupashaving
hypoglycemia unawareness but none in
the C-group. On the other hand, the
Clarke test classiﬁed 24 of 25 H-group
subjects as having hypoglycemic un-
awareness and 1 of 25 as inconclusive.
Again, all of the type 1 diabetic subjects
from the C-group were classiﬁed as hav-
ing normal awareness using the second
test.
The mean score for the Edinburgh
scale in euglycemia was not different be-
tween the groups (21.1  2.7 vs. 20.5 
1.9 for the H-group and C-group, respec-
tively). With respect to the signs/
symptoms response during the acute
induction of hypoglycemia, type 1 dia-
beticsubjectsintheH-groupincreasedon
average 46% on the Edinburgh scale be-
tween euglycemia and hypoglycemia,
whereas those in the C-group increased
163% between both situations.
Table 1—Characteristics of study subjects
H-group C-group P value
n 25 20
Sex (male/female) 11/14 11/9 NS
Age (years) 34.6  7.8 33.5  8.7 NS
Type 1 diabetes duration (years) 16.1  6.3 14.0  6.5 NS
A1C (%) 6.6  1.0 6.7  0.7 NS
Total cholesterol (mg/dl) 171  30 167  34 NS
LDL cholesterol (mg/dl) 107  26 101  24 NS
HDL cholesterol (mg/dl) 52  12 55  11 NS
Triglycerides (mg/dl) 54  26 47  20 NS
Systolic blood pressure (mmHg) 107  12 108  13 NS
Diastolic blood pressure (mmHg) 71  97 3  10 NS
BMI (kg/m
2) 23.1  2.9 23.5  2.3 NS
Smokers (%) 0 0 NS
Data are means  SD.
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With respect to the results obtained from
the blinded CGM system data in type 1
diabetic patients, it was not surprising
that the H-group subjects presented
higher percentages of values and area un-
der the curve 70 mg/dl with respect to
the C-group (14.2  8.9 vs. 6.3  7.0%
of values 70 mg/dl, P  0.02 and 2.4 
1.8 vs. 0.6  1.0 mg/dl area under the
curve for low values, P  0.01 for the
H-group and C-group, respectively). Re-
garding glucose variability, MAGE was
signiﬁcantly higher in the H-group than
in the C-group (136  29 vs. 101  28
mg/dl, P  0.01).
FMD
Subjects from the H-group displayed
lower percentages of FMD response to
ischemia with respect to type 1 diabetic
patients from the C-group (6.52  2.92
vs. 8.62  3.13%, P  0.05) (Table 2).
Both type 1 diabetic groups were com-
pared with the Healthy-Control Group
(22 subjects, 12 women, aged 32.7  6.8
years), and lower percentages of dilata-
tion in the FMD test were found when
compared with those obtained in the
comparativegroup(9.412.20%forthe
Healthy-Control Group).
cIMT and fIMT
As shown in Table 2, all of the measures
performed in carotid and femoral sites
were higher in the H-group than in the
C-group. With respect to carotid arteries,
both cIMT and cIMTcomp were higher in
the H-group than in the C-group (cIMT
0.53  0.09 vs. 0.47  0.08 mm; P 
0.05; cIMTcomp 0.59  0.13 vs. 0.47 
0.07 mm, P  0.02). In addition, fIMT
was also lower in the C-group (0.51 
0.17 vs. 0.39  0.09 mm, P  0.05).
Whereasatheroscleroticplaqueswerede-
tectedineitherthecarotidorfemoralarea
in 10 of 25 subjects from the H-group,
none were detected in the C-group.
As expected, the H-group also had
thickercIMTandfIMTwithrespecttothe
healthy control group, but there were no
differences between the C-group and the
healthy control group (cIMT 0.47  0.05
mm and fIMT 0.39  0.05 mm for the
healthy control group) (Table 2).
Inﬂammation and endothelial
function markers
vWF, ﬁbrinogen, leukocytes, and sICAM-1
weresigniﬁcantlyhigherintheH-group.In
contrast,nodifferencesbetweenthegroups
were observed with respect to the basal de-
termination of hs-CRP, soluble E-selectin,
and 1-IL (Table 3).
All previously mentioned parameters
were also measured in the H-group and
C-group after 30 min of hypoglycemia
(nadir glucose concentrations: 39  5 vs.
40  4 mg/dl, NS for the H-group and
C-group, respectively). There were no
signiﬁcant differences between the
groups in changes evoked by hypoglyce-
mia (Table 3).
In the multiple linear regression anal-
ysis, the allocation in the H-group deter-
mined cIMTcomp ( 0.082, P  0.02)
independently from the other covariates:
age ( 0.008, P  0.001), sex, disease
duration, BMI, systolic blood pressure,
A1C, MAGE, and LDL cholesterol (
0.001, P  0.03). The complete model
explained 73% of cIMTcomp.
CONCLUSIONS — Our ﬁndings
suggest that repeated hypoglycemic epi-
sodes in type 1 diabetic subjects are asso-
ciated with a worse prognosis in terms of
preclinical atherosclerosis proﬁle repre-
sentednotonlybyabnormalitiesinendo-
thelial function but also by an increase in
IMT in both carotid and femoral sites.
Type 1 diabetes is associated with
premature arterial disease. There are
somestudiesthathavepreviouslydemon-
strated endothelial dysfunction using
Table 2—Mean values of carotid, femoral, and brachial ultrasound measures: FMD and IMT
results and comparisons between groups
H-group C-group P value
n 25 20
Brachial artery measures
Baseline brachial diameter (mm) 4.13  0.76 3.80  0.74 NS
Maximal FMD (%) 6.52  2.92 8.62  3.13 0.05
Carotid artery measures
Mean common carotid (cIMT, mm) 0.53  0.09 0.47  0.08 0.05
Mean carotid bifurcation (mm) 0.67  0.18 0.50  0.07 0.02
Mean internal carotid (mm) 0.58  0.20 0.45  0.09 0.02
Mean carotid composite (cIMTcomp, mm) 0.59  0.13 0.47  0.07 0.01
Subjects with carotid plaques 8/25 0
Femoral artery measures
Mean common femoral (fIMT, mm) 0.51  0.17 0.39  0.09 0.05
Subjects with femoral plaques (%) 5/25 0
Subjects with plaques in any carotid/femoral areas 10/25 0
Data are means  SD.
Table 3—Endothelial function and inﬂammation biochemical markers measured in both
groups in euglycemia and hypoglycemia
H-group C-group P value
n 25 20
Euglycemia
vWF euglycemia (%) 119  29 93  26 0.02
Fibrinogen euglycemia (g/l) 2.82  0.64 2.29  0.44 0.02
Leukocytes (10
3/l) 7.0  1.8 5.6  1.4 0.05
sICAM-1 euglycemia (ng/ml) 408  224 296  95 0.05
hs-CRP euglycemia (mg/dl) 0.23  0.30 0.15  0.17 NS
E-selectin euglycemia (ng/ml) 44  21 49  25 NS
1-IL euglycemia (pg/ml) 2.92  6.15 1.30  2.65 NS
% increase in hypoglycemia*
vWF 3.24  12.85 16.97  31.91 NS
Fibrinogen 2.84  12.55 10.45  23.27 NS
sICAM-1 4.15  11.76 6.12  13.31 NS
hs-CRP 	2.35  9.02 20.35  61.25 NS
Soluble E-selectin 4.74  10.79 0.47  11.30 NS
1-IL 41.55  143.30 33.30  152.75 NS
DataaremeansSD.*Expressedaspercentageincreasedineachvariablewithrespecttothebaselineresult.
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In addition, our article is not the ﬁrst to
demonstrate a higher mean cIMT in sub-
jects with type 1 diabetes compared with
a control group. In our study, the FMD
response to ischemia was lower in sub-
jects with type 1 diabetes compared with
healthy control subjects, demonstrating
early alteration of vascular function. In
addition, in patients with repeated epi-
sodes of hypoglycemia, IMT (carotid and
femoral) was higher than in the healthy
control group. Hypertension, dyslipide-
mia, smoking, and urinary albumin ex-
cretion have been related to cIMT and
atherosclerosis in type 1 diabetes (7). In
our study, including patients with type 1
diabeteswithoutCVDriskfactorsandmi-
crovascular and macrovascular complica-
tions, LDL cholesterol was also associated
with the variation in cIMT.
The EDIC study showed that inten-
siveinsulintherapyslowedtheincrement
of cIMT in type 1 diabetes (7). It has been
found that acute hyperglycemia induces
vascular changes and inﬂammatory re-
sponse and alters myocardial ventricular
repolarization in type 1 diabetes (21,22).
Despite the assumption that glucose vari-
ability is greater than that in type 2 diabe-
tes, data concerning whether glucose
ﬂuctuations are an independent risk fac-
tor for complications in type 1 diabetes
are still controversial (23). However, it
hasbeensuggestedthatahighmeandaily
bloodglucose,butnotglucosevariability,
is related to arterial stiffness in patients
with type 1 diabetes using CGM and a
hyperglycemic clamp (24). In addition,
Wentholt et al. (10) failed to demonstrate
arelationbetweenhighglucosevariability
and elevated levels of a surrogate marker
ofvasculardamage.Inourstudyandcon-
sidering all patients with type 1 diabetes
as a whole, MAGE was not independently
associated with cIMT.
Hypoglycemia is the most common
andthemostfearedsideeffectofintensive
insulin therapy and frequently is the ma-
jor barrier to achieving glucose control as
normal as possible (4). In the short term,
the acute hemodynamic changes induced
by hypoglycemia may precipitate and ag-
gravate a vascular event during an acute
episode (25). In the long term, especially
if hypoglycemia is repeated, the abnor-
malities in coagulation, ﬁbrinolysis, and
inﬂammation associated with it could be
related to the induction and progression
of atherosclerosis. In our study, in addi-
tiontotheinductionofhypoglycemiaun-
awareness, repeated episodes of
hypoglycemia were related to a worse
prognosis in terms of preclinical athero-
sclerosis. Considering endothelial func-
tion, FMD was signiﬁcantly reduced in
type 1 diabetic subjects with repeated ep-
isodes of hypoglycemia compared with
that in those patients without these epi-
sodes. Accordingly, coagulation markers
of endothelial damage and acute-phase
inﬂammation markers were signiﬁcantly
higher in the former group.
For structural changes, a comprehen-
siveevaluationofcarotidarteriesgavesig-
niﬁcant higher values of IMT in subjects
having repeated episodes of hypoglyce-
mia. The multivariate regression analysis
conﬁrmed the association of repeated ep-
isodes of hypoglycemia and cIMTcomp
independently of the other CVD risk fac-
tors considered. Likewise, data on IMT
from femoral arteries conﬁrmed that pre-
clinical atherosclerosis was aggravated by
repeated episodes of hypoglycemia not
only in the carotid artery but also in pe-
ripheral vascular sites. It is noteworthy
that in contrast to the ﬁndings with FMD,
for IMT, differences with respect to the
healthy control group were only signiﬁ-
cant in patients with type 1 diabetes and
repeated episodes of hypoglycemia. This
observation suggests that in addition to
alterationsinendothelialfunctionthatoc-
cur early in type 1 diabetes, recurring ep-
isodes of hypoglycemia could be
considered an aggravating or accelerating
factor.Thereisneithercompleteinforma-
tion concerning type 1 diabetes-speciﬁc
determinants of vascular damage and
their interrelationships nor the minimal
timeofexposurerequiredforapreclinical
cardiovascular alteration. Our results
point to repeated episodes of hypoglyce-
mia being considered as a new potential
riskfactor.Theexposuretoriskfactorlev-
elsthroughoutthelifespaninyoungpeo-
ple promotes the accumulation of
subclinical atherosclerosis, which will be
transformed into CVD events, but typi-
cally not until much later in life.
As mentioned previously, there are
recent studies speciﬁcally designed to ad-
dress the effects of acute hypoglycemia,
conﬁrming its proinﬂammatory and pro-
thrombotic effects (11,12). For some of
the inﬂammatory markers (leukocytes
and sICAM-1). we detected signiﬁcantly
higher values at baseline in subjects with
repeated hypoglycemia. In both group of
subjects with type 1 diabetes, insulin-
induced hypoglycemia elicited a hetero-
geneousnonsigniﬁcantriseinendothelial
and inﬂammatory markers without any
difference in the response observed with
respect to the presence or absence of fre-
quent hypoglycemia. This lack of re-
sponse to provoked hypoglycemia in
comparison with previous studies could
berelated,atleastinpart,tolimitationsof
the experimental conditions of our proto-
col. In fact, the study of acute effects of
hypoglycemia was not considered the
main objective of our study, and the pro-
tocol was not designed to accurately as-
sess mechanistic roles. As examples, we
included a shorter period of hypoglyce-
mia(30min)beforeextractionandwedid
not control for insulin levels and the po-
tential effect on vascular function. More-
over, and in contrast with some previous
studies,wedidnotexcludethosesubjects
with hypoglycemia unawareness because
thisclinicalconditionwasseeninpatients
fulﬁlling our inclusion criteria. Further
research is required to fully understand
the link between repeated episodes of hy-
poglycemia and a worse prognosis in
termsofpreclinicalatherosclerosisintype
1 diabetes. However, the putative role for
endothelial and inﬂammatory factors in
the mediation of hypoglycemia-induced
vascular damage has to be taken into
consideration.
Insummary,inadditiontotheinduc-
tionofhypoglycemiaunawarenessandan
increased risk for severe hypoglycemia,
repeated episodes of hypoglycemia could
be related to and considered an aggravat-
ing factor for the preclinical atherosclero-
sis proﬁle of type 1 diabetes.
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